Veozah Alternatives: What Else Treats Hot Flashes, and What It Actually Costs

Is there a generic for Veozah (fezolinetant)?

No, and it isn't close. Fezolinetant, Veozah's active ingredient, is still under patent and regulatory exclusivity, and the earliest a generic manufacturer can even file a legal challenge is May 13, 2027 — the drug's NCE-1 date, four years after its May 2023 FDA approval. Filing eligibility isn't the same as a product on the shelf, either: based on the current patent and exclusivity landscape, the estimated generic launch date sits around March 2034. Litigation or a settlement could move that date, but as of now, a 'fezolinetant coupon' and a 'Veozah coupon' point to the exact same drug, because there's nothing else to compare it to.

That's the reason this page exists. With no cheaper version of the same molecule to point you toward, the honest alternatives split into two real categories: other treatments that work through a different mechanism entirely, hormonal or not. Both are covered below, priced.

Why does Veozah cost so much if there's no generic competing with it?

Patent protection is most of the answer. Astellas' own list price for a 30-tablet bottle is $583.50 as of early 2026, and pharmacy counters typically post something closer to $773 to $778 before any discount — a newly launched, patent-protected, single-source drug with no generic competitor pulling it down, the same dynamic that keeps most new brand-name drugs expensive in their first several years on the market. A SingleCare or GoodRx coupon brings that down meaningfully, and for commercially insured women, the Astellas copay card is the number that actually matters — though that card explicitly excludes Medicare, Medicaid, and Tricare. The full breakdown of every lever that moves Veozah's price, including what Medicare pays and how prior authorization works, lives at Veozah's real 2026 cost.

What are the real alternatives to Veozah for hot flashes?

Strip away the mechanism talk and there are really only two doors here. One is hormone therapy itself — estrogen, the treatment The Menopause Society still calls the most effective option available for hot flashes, if your history doesn't rule it out. The other is the small set of older, non-hormonal generic drugs that were being prescribed off-label for hot flashes long before Veozah existed, several of which The Menopause Society's 2023 nonhormone position statement continues to recommend on real evidence: gabapentin, oxybutynin, and low-dose paroxetine, alongside fezolinetant itself. What that statement notably does not recommend is clonidine, despite it still being commonly prescribed and dirt cheap — more on that trade-off below.

None of these is a straight swap for Veozah. HRT works differently and reaches further than a hot-flash-only drug; the older generics carry less robust trial data and side-effect profiles Veozah's SKYLIGHT trials were specifically designed around. What follows is each option, priced, with its real trade-off named plainly.

HRT: Alloy, Winona, and estrogen-based options, priced

If nothing in your history rules out hormones, HRT is the option Veozah was built to stand in for when hormones aren't an option — which makes it worth ruling in or out first, not last. Winona prices its FDA-approved products à la carte: a progesterone-only capsule from $39 a month, an estrogen-plus-progesterone cream at $89, and an estrogen patch at $149, with no consult fee attached. Alloy runs a one-time $49 consult, then $100 a month for its estradiol patch (billed every three months) plus progesterone priced separately from $23 a month, for roughly $123 a month combined — or from $39.99 a month if the oral estradiol pill fits you better than a patch. Alloy's physicians are Menopause Society–certified specifically, which is worth something if you want that credential bar; Winona's per-product pricing is generally the lower number if cost is the deciding factor.

The honest caveat: this only works if you're actually a reasonable HRT candidate. A personal history of breast cancer, unexplained vaginal bleeding, active liver or gallbladder disease, or a personal history of blood clots typically rules hormone therapy out — which is exactly the population Veozah exists to serve. If any of that applies to you, skip ahead to the non-hormonal options below rather than treating HRT as a default cheaper swap. For the fuller side-by-side on efficacy and safety between the two, see Veozah vs. HRT.

Low-dose paroxetine (Brisdelle and the generic) for hot flashes, priced

This is the only non-hormonal pill besides Veozah with its own FDA approval specifically for hot flashes, which makes it worth understanding precisely rather than lumping in with the other off-label generics. Brisdelle is a 7.5mg paroxetine mesylate capsule, and a generic version of that exact formulation now exists — priced at roughly $52 a month with a GoodRx coupon, well under brand Brisdelle's typical retail of $164 a month and up. That's a specific, deliberately low dose, distinct from the paroxetine tablets prescribed for depression and anxiety at higher strengths, which some clinicians instead prescribe off-label at a low dose for hot flashes — and those standard-strength generics are dramatically cheaper again, often $4 to $25 a month with a coupon.

The trade-off against Veozah is real but different in kind: paroxetine is an SSRI, so it carries its own withdrawal considerations if stopped abruptly, potential sexual side effects, and — worth flagging directly if it applies to you — an interaction with tamoxifen that matters for some women with a breast cancer history. It doesn't carry Veozah's liver-injury boxed warning or the liver-monitoring requirement that comes with it.

Gabapentin for hot flashes and night sweats, priced

Gabapentin has one of the stronger evidence bases among the non-hormonal generics — The Menopause Society's 2023 position statement lists it among its recommended options for hot flash relief, alongside fezolinetant itself. It's also cheap: a GoodRx or SingleCare coupon typically brings a month's supply down to somewhere between $8 and $25, depending on the dose your clinician prescribes and how many pills that works out to. The catch is the schedule, not the price — gabapentin is taken multiple times across the day rather than once, unlike Veozah's single daily tablet, and drowsiness and dizziness are common enough in the first few weeks that many clinicians start it at night specifically because of that.

It's a reasonable first non-hormonal option to raise with a clinician precisely because the evidence is solid and the downside of trying it is low-cost and reversible — nothing about starting gabapentin closes off Veozah, HRT, or anything else as a next step if it doesn't work for you.

Clonidine and oxybutynin: the other non-hormonal options, priced

These two get grouped together because they're both cheap, both older, and both land on opposite sides of NAMS's current recommendations — worth knowing before either shows up on a prescription pad as 'the cheap option.'

Clonidine is the cheapest drug on this entire page, often just $3 to $5 a month generically. It's also the one The Menopause Society's 2023 statement specifically lists as not recommended, based on weak evidence of benefit weighed against real side effects — dry mouth shows up in roughly 4 of every 10 patients, along with dizziness and drowsiness, and stopping it abruptly can trigger a dangerous rebound spike in blood pressure that requires a slow taper to avoid. Oxybutynin sits on the recommended side of that same statement, priced a little higher at roughly $13 to $20 a month generically. It's FDA-approved for overactive bladder rather than hot flashes specifically, so this is an off-label use here too, and the one caveat worth carrying into a longer-term conversation with your prescriber is that long-term anticholinergic use — the drug class oxybutynin belongs to — has been linked to cognitive-decline risk in older adults in a growing body of research.

Are cooling products, CBT-I, or lifestyle changes worth trying first?

Some of them, according to NAMS — but not the ones marketed the loudest. The 2023 nonhormone position statement puts cognitive behavioral therapy, clinical hypnosis, and weight loss on its recommended list, with real evidence behind each for reducing how much hot flashes interfere with daily life and sleep. A newer 2025 scoping review comparing the two behavioral approaches found clinical hypnosis outperforming CBT specifically on hot flash frequency and severity, while CBT's stronger evidence is for how bothersome and disruptive the symptoms feel — a real distinction if frequency itself, versus how much it's wrecking your sleep and mood, is your bigger complaint.

What the same statement lists as not recommended, for lack of supporting evidence on hot flashes specifically, is worth knowing too: cooling products, yoga, general exercise, herbal supplements including soy extracts, cannabinoids, acupuncture, and chiropractic care. That's not the same as 'harmful' or 'not worth doing for other reasons' — exercise and weight management both carry real benefit for cardiovascular and bone health regardless of what they do for hot flashes specifically, and a cooling pillow costs nothing to try. It just means none of that list has been shown to move the needle on hot flash frequency the way CBT, hypnosis, or the prescription options above have, so it's fair to treat them as a comfort layer alongside a real treatment rather than a substitute for one.

Can you get compounded fezolinetant as a cheaper workaround?

No — and this is worth being direct about, because the compounded-GLP-1 wave has trained a lot of people to assume a compounding pharmacy is always the answer to a high drug price. It isn't here. Compounding under FDA's 503A framework is legal only when a licensed pharmacy prepares a drug for a specific patient with a documented clinical need the FDA-approved product can't meet — most commonly during a declared national shortage, or for a patient with a genuine allergy to an inactive ingredient. Fezolinetant has no reported national shortage; Veozah is stocked at standard retail pharmacies without the supply gaps that opened the door for compounded tirzepatide and semaglutide. A search for a legitimate pharmacy currently compounding and selling fezolinetant turns up nothing — no verified 503A or 503B source offering it as a cost-saving swap. If you come across a site advertising 'compounded fezolinetant' or a 'fezolinetant alternative' at a steep discount, treat that as a red flag rather than a find.

What a full year of Veozah vs. each alternative actually costs — and how to choose

• Veozah, copay card (commercially insured): about $330/yr — the free first month plus 11 refills at roughly $30 each.
• Veozah, cash with a coupon: roughly $5,604 to $6,540/yr, depending on pharmacy; full retail with no coupon runs $9,276 to $9,336/yr.
• Alloy, patch + progesterone: about $1,525 in year one including the $49 consult, closer to $1,476/yr ongoing; the pill-only route runs about $480/yr in medication.
• Winona, à la carte: roughly $1,070 to $2,260/yr depending on which product or combination you're prescribed.
• Generic paroxetine, Brisdelle-equivalent 7.5mg: about $624/yr with a coupon; brand Brisdelle runs $1,968/yr or more at typical retail.
• Generic paroxetine, standard low dose off-label: roughly $48 to $300/yr.
• Generic gabapentin: roughly $96 to $300/yr, dose-dependent.
• Generic clonidine: roughly $36 to $60/yr — cheapest on this page, but not NAMS-recommended.
• Generic oxybutynin: roughly $156 to $240/yr.

Laid out this way, the choice mostly comes down to three questions in order. First: are you a reasonable HRT candidate, medically? If yes, and cost is the concern, Winona and Alloy both undercut Veozah's cash price by a wide margin, and HRT carries the strongest efficacy data of anything on this page. Second, if hormones are off the table: does your insurance cover Veozah with a workable copay, or does the copay card apply to you? At roughly $30 a month, that's competitive with — not more expensive than — several of the generics here, and it comes with the specific SKYLIGHT trial data and once-daily dosing Veozah was built around. Third, if you're paying cash and the generics are the realistic starting point: gabapentin and oxybutynin have NAMS's own backing and predictable, low costs; low-dose paroxetine adds an FDA approval specifically for this symptom, at a somewhat higher price than the other generics; clonidine is cheapest by far but carries the specific caution above. None of these choices is permanent — plenty of women start with a cheap generic, and move to Veozah or HRT later if it doesn't do enough.